Project Name:Erlotinib
Registration Classification:3+6
Formulations and specifications :Tablets: 25mg, 100mg, 150mg
Indications:For locally advanced or metastatic non-small cell lung cancer (NSCLC) after at least one previously failure chemotherapy .
Original Research Company:Roche
Progress :Pharmaceutical Research in progress
Category :Cancer drug